Wettersten Nicholas, Maisel Alan S
Division of Cardiovascular Medicine, University of California, San Diego, La Jolla.
Division of Cardiovascular Medicine, Veterans Affairs Medical Center, San Diego, La Jolla, Calif.
Am J Med. 2016 Jun;129(6):560-7. doi: 10.1016/j.amjmed.2016.01.013. Epub 2016 Feb 1.
Biomarkers have become an integral part of practicing medicine, especially in heart failure. The natriuretic peptides are commonly used in the evaluation of heart failure, but their role extends beyond diagnosis and includes risk stratification and management of heart failure patients. Newer biomarkers have arrived and are becoming part of routine care of heart failure patients. Both ST2 and high-sensitivity troponin have significant prognostic value for mortality, but also may assist in the titration of medical therapy. Procalcitonin can help guide appropriate antibiotic use in patients with heart failure. The ability to appropriately use and interpret these biomarkers is imperative to the care of heart failure patients, especially as these newer biomarkers become widely used.
生物标志物已成为医学实践中不可或缺的一部分，尤其是在心力衰竭领域。利钠肽常用于心力衰竭的评估，但其作用不仅限于诊断，还包括心力衰竭患者的风险分层和管理。更新的生物标志物已经出现，并正成为心力衰竭患者常规护理的一部分。ST2和高敏肌钙蛋白对死亡率都有显著的预后价值，还可能有助于调整药物治疗。降钙素原有助于指导心力衰竭患者合理使用抗生素。正确使用和解读这些生物标志物的能力对于心力衰竭患者的护理至关重要，尤其是随着这些更新的生物标志物被广泛应用。
